Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This is an adaptive Phase 1b/2 trial design. It is randomized, double-blind,
placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics,
safety and tolerability of BXCL-501 dosing in adult (65 years and older) males and females
with acute agitation associated with dementia. Evaluation of 3 doses are planned.